3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Ovarian Neoplasms
32
Breast Neoplasms
18
Neoplasms
9
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
7
Sarcoma
6
Prostatic Neoplasms
6
Fanconi Anemia, Complementation Group D1
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Mesothelioma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumors
2
Wilms Tumor
1
Interventions
Cisplatin
33
Radiotherapy
23
Cetuximab
18
Paclitaxel
14
Docetaxel
14
pembrolizumab
13
Carboplatin
12
Fluorouracil
10
Radiotherapy, Intensity-Modulated
8
Nivolumab
8
Drug Therapy
7
Erlotinib Hydrochloride
6
Panitumumab
5
dacomitinib
4
Radiation
4
Methotrexate
4
Esophagectomy
4
130-nm albumin-bound paclitaxel
4
durvalumab
3
ON 01910
3
Leucovorin
3
Gemcitabine
3
Chemoradiotherapy
3
vandetanib
2
palbociclib
2
osimertinib
2
nedaplatin
2
fludarabine
2
cabazitaxel
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Squamous Cell
×
olaparib
×
Clear all
NCT02308072
2026-05-22
ORCA-2
University College, London
Phase 1
Completed
16 enrolled